Novavax (NVAX) Capital Expenditures Growth (5y) (2015 - 2026)
Novavax (NVAX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Novavax | 788.01 Mn | -2.33 Mn | 108.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -32.52% |
| Dec 31, 2025 | 19.39% |
| Sep 30, 2025 | -16.43% |
| Jun 30, 2025 | -15.26% |
| Mar 31, 2025 | 66.41% |
| Dec 31, 2024 | 19.33% |
| Sep 30, 2024 | 22.30% |
| Jun 30, 2024 | -20.49% |
| Mar 31, 2024 | 44.16% |
| Dec 31, 2023 | -156.12% |
| Sep 30, 2023 | 125.39% |
| Jun 30, 2023 | 136.04% |
| Mar 31, 2023 | 90.44% |
| Dec 31, 2022 | -150.25% |
| Sep 30, 2022 | 121.99% |
| Jun 30, 2022 | -73.31% |
| Mar 31, 2022 | 73.06% |
| Sep 30, 2021 | 42.70% |
| Jun 30, 2021 | 55.46% |
| Mar 31, 2021 | 10.47% |